Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma

Giovanni Citterio, T Calimeri, AJM Ferreri

Research output: Contribution to journalArticle

Abstract

© 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Primary central nervous system lymphoma (PCNSL) retains peculiar biological and clinical characteristics and a worse prognosis with respect to other comparable lymphomas. The need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in severe treatment-related toxicities, mainly neurologic, which are frequently as disabling as the disease itself. Areas covered: Several emerging combined therapies are addressed that focus on treating PCNSL. The prognosis has improved in the last years but several questions remain unanswered and the research of more effective therapies goes on. Information and data were obtained from direct authors’ experience and a PubMed search of recent peer-reviewed original articles, review articles, and clinical guidelines. Expert commentary: The substantial progress observed in PCNSL has to be ascribed to a carefully combination of standard chemotherapeutic drugs. High-dose methotrexate-based polychemotherapy followed by mainteinance therapy offers one of the best chances to control the disease. Major issues that deserve many efforts by researchers are the definition of optimal consolidation treatment and a shared management of specific conditions such as elderly population and intra-ocular localization. © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Original languageEnglish
Pages (from-to)379-393
Number of pages15
JournalExpert Review of Neurotherapeutics
Volume18
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Lymphoma
Central Nervous System
Therapeutics
Combination Drug Therapy
PubMed
Methotrexate
Pharmaceutical Preparations
Nervous System
Radiotherapy
Research Personnel
Guidelines
Drug Therapy
Research
Population

Cite this

Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. / Citterio, Giovanni; Calimeri, T; Ferreri, AJM.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 5, 2018, p. 379-393.

Research output: Contribution to journalArticle

@article{6f448c15c29a493dba307f7d08b76b2a,
title = "Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma",
abstract = "{\circledC} 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Primary central nervous system lymphoma (PCNSL) retains peculiar biological and clinical characteristics and a worse prognosis with respect to other comparable lymphomas. The need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in severe treatment-related toxicities, mainly neurologic, which are frequently as disabling as the disease itself. Areas covered: Several emerging combined therapies are addressed that focus on treating PCNSL. The prognosis has improved in the last years but several questions remain unanswered and the research of more effective therapies goes on. Information and data were obtained from direct authors’ experience and a PubMed search of recent peer-reviewed original articles, review articles, and clinical guidelines. Expert commentary: The substantial progress observed in PCNSL has to be ascribed to a carefully combination of standard chemotherapeutic drugs. High-dose methotrexate-based polychemotherapy followed by mainteinance therapy offers one of the best chances to control the disease. Major issues that deserve many efforts by researchers are the definition of optimal consolidation treatment and a shared management of specific conditions such as elderly population and intra-ocular localization. {\circledC} 2018 Informa UK Limited, trading as Taylor & Francis Group.",
author = "Giovanni Citterio and T Calimeri and AJM Ferreri",
year = "2018",
doi = "10.1080/14737175.2018.1462700",
language = "English",
volume = "18",
pages = "379--393",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma

AU - Citterio, Giovanni

AU - Calimeri, T

AU - Ferreri, AJM

PY - 2018

Y1 - 2018

N2 - © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Primary central nervous system lymphoma (PCNSL) retains peculiar biological and clinical characteristics and a worse prognosis with respect to other comparable lymphomas. The need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in severe treatment-related toxicities, mainly neurologic, which are frequently as disabling as the disease itself. Areas covered: Several emerging combined therapies are addressed that focus on treating PCNSL. The prognosis has improved in the last years but several questions remain unanswered and the research of more effective therapies goes on. Information and data were obtained from direct authors’ experience and a PubMed search of recent peer-reviewed original articles, review articles, and clinical guidelines. Expert commentary: The substantial progress observed in PCNSL has to be ascribed to a carefully combination of standard chemotherapeutic drugs. High-dose methotrexate-based polychemotherapy followed by mainteinance therapy offers one of the best chances to control the disease. Major issues that deserve many efforts by researchers are the definition of optimal consolidation treatment and a shared management of specific conditions such as elderly population and intra-ocular localization. © 2018 Informa UK Limited, trading as Taylor & Francis Group.

AB - © 2018 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Primary central nervous system lymphoma (PCNSL) retains peculiar biological and clinical characteristics and a worse prognosis with respect to other comparable lymphomas. The need for high doses of chemotherapy to achieve valid drug concentrations in cerebral tissues and/or radiotherapy results in severe treatment-related toxicities, mainly neurologic, which are frequently as disabling as the disease itself. Areas covered: Several emerging combined therapies are addressed that focus on treating PCNSL. The prognosis has improved in the last years but several questions remain unanswered and the research of more effective therapies goes on. Information and data were obtained from direct authors’ experience and a PubMed search of recent peer-reviewed original articles, review articles, and clinical guidelines. Expert commentary: The substantial progress observed in PCNSL has to be ascribed to a carefully combination of standard chemotherapeutic drugs. High-dose methotrexate-based polychemotherapy followed by mainteinance therapy offers one of the best chances to control the disease. Major issues that deserve many efforts by researchers are the definition of optimal consolidation treatment and a shared management of specific conditions such as elderly population and intra-ocular localization. © 2018 Informa UK Limited, trading as Taylor & Francis Group.

U2 - 10.1080/14737175.2018.1462700

DO - 10.1080/14737175.2018.1462700

M3 - Article

VL - 18

SP - 379

EP - 393

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 5

ER -